Maricann Group (CSE:MARI) has further solidified its stance into the biotech business of cannabis by completing (August 22) the acquisition of NanoLeaf Technologies, a company which has worked on a cannabinoid standardized dose soft gel capsule in Vesisorb a nano-dispersed drug.
“The acquisition… will significantly enhance Maricann’s growth trajectory by expanding our product portfolio, delivering access to new markets, and strengthening our pipeline of future products,” Ben Ward, CEO of Maricann said. The acquisition is expected to be done by the end of September.
Through this acquisition, Maricann wants to get closer to solving a challenge currently ailing the cannabis industry: “finding a predictable delivery mechanism of cannabinoids in an oral dosing format.”

Cannabinoids are a fat-soluble compound that have low solubility, leading to low dissolution rates and significant first-pass liver metabolism resulting in low and unpredictable oral cannabinoid bioavailability. This poor solubility not only gives low oral bio-availability but also leads to high inter- and intra-subject variability and lack of dose proportionality.

NanoLeaf focused on the extraction of tetrahydrocannabinol (THC) and cannabinoids. As part of the acquisition, Maricann will gain access to NanoLeaf’s exclusive market rights for both their extraction and drug delivery technology.
Maricann also gets a brand new portfolio of patents commercialized globally through various markets like pharmaceuticals and cosmetics.
Recently Maricann announced it would be raising $35 million as part of a private placement.

Maricann gets new tech

NanoLeaf’s drug delivery technology, VESIsorb boosts the bioavailability of cannabinoid oil, according to the company, by 600 percent.
The company indicated their technology can provide results in various forms like soft gels, liquid capsules, lotions, sprays, drinks and water soluble powder. Potentially opening the door for Maricann to explore distinct cannabinoid delivery methods.
Maricann began trading on April 24 of this year following its inception four years before.
The company has steadily been building its collection of licenses from Health Canada since 2014 when it first obtained a cultivation license. In September of last year, Maricann obtained its license for the sale of cannabis extracts.

Investor Takeaway

Thanks to this acquisition Maricann has obtained a fascinating technology they hope will lead to new drug delivery methods for cannabis as the medical market in Canada continues to grow and the demand only gets bigger.
On Wednesday, August 23, Maricann saw a 0.74 percent decline to its stock. After market close, the company’s shares were priced at $1.35.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less